FilingSEC EDGAR6-K
Alterity Therapeutics Announces Additional Phase 2 Analysis Results for ATH434
· SEC accepted
StagePhase 2
Filing content
The company announced additional Phase 2 analysis results for its MSA treatment ATH434, showing a 52% slowing of functional decline compared to placebo.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…